SUO Annual Meeting 2021
SUO Annual Meeting 2021
Society of Urologic Oncology 22nd Annual Meeting
Advertisement
GU Oncology Now EditorsSUO Annual Meeting 2021 | December 3, 2021
Active surveillance, standard of care for low-risk prostate cancer, may be safe for patients with intermediate-risk disease.
Read More
GU Oncology Now EditorsSUO Annual Meeting 2021 | September 19, 2022
Researchers evaluate PSA screening frequency and the effect of different screening intensities on prostate cancer diagnoses.
GU Oncology Now EditorsSUO Annual Meeting 2021 | February 5, 2024
The CxBladder Monitor urine test is feasible and safe for patients on surveillance for NMIBC.
GU Oncology Now EditorsSUO Annual Meeting 2021 | March 6, 2023
Urologists contribute the most to Medicare Part D medication costs, likely because of high-cost urologic cancer care meds.
GU Oncology Now EditorsSUO Annual Meeting 2021 | December 2, 2021
Researchers used a natural language processing method to analyze kidney function inclusion criteria for a clinical trial.
GU Oncology Now EditorsSUO Annual Meeting 2021 | September 19, 2022
Researchers observed treatment for MIBC in academic facilities didn’t mitigate poorer outcomes for disadvantaged ...
GU Oncology Now EditorsSUO Annual Meeting 2021 | December 2, 2021
Researchers evaluated the new AUA risk stratification system for survival in patients with clear cell or papillary RCC.
GU Oncology Now EditorsSUO Annual Meeting 2021 | November 30, 2022
177Lu-PSMA-I&T followed by radical prostatectomy with PLND appeared safe in patients with high-risk prostate cancer.
GU Oncology Now EditorsSUO Annual Meeting 2021 | September 19, 2022
For prostate cancer patients, variables like definitive treatment and time to treatment initiation are inferior at HSDPs.
GU Oncology Now EditorsSUO Annual Meeting 2021 | December 1, 2021
Researchers identified survival predictors in patients with renal cell carcinoma with inferior vena cava thrombus.
GU Oncology Now EditorsSUO Annual Meeting 2021 | December 1, 2021
Cost analysis was used to evaluate whether transperineal prostate biopsy is superior to standard transrectal prostate biopsy.
GU Oncology Now EditorsSUO Annual Meeting 2021 | December 1, 2021
Active surveillance doesn’t result in inferior renal function compared with partial nephrectomy in patients with ...
Advertisement
Advertisement
Advertisement